Back to results
US 2022/0175767 A1Published application
Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
AssigneeEmory University
InventorsMalathy Shanmugam, Richa Bajpai
Life of this patent
Estimating the term…
Abstract
In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.
Claims10
A method of comprising,
- a) isolating a sample of cancer cells from a subject,
- b) mixing the sample with mitochondrial complex II, succinate, and ubiquinone;
- and
- c) measuring succinate ubiquinone reductase (SQR) activity providing measured SQR activity.
1 more element
A method of diagnosing and treating multiple myeloma comprising,
- a) isolating a sample of myeloma cells from a subject,
- b) mixing the sample with mitochondrial complex II, succinate, and ubiquinone;
- and
- c) measuring succinate ubiquinone reductase (SQR) activity providing measured SQR activity;
- and
- d) treating the subject with venetoclax if the measured SQR activity is lower than a control level.
3 more elements
Dependencies are inferred from the claim text.